Eravacycline: A Review in Complicated Intra-Abdominal Infections
暂无分享,去创建一个
[1] J. Solomkin,et al. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] L. Tsai,et al. 1978. Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection , 2018, Open Forum Infectious Diseases.
[3] E. Efimova,et al. 1976. Pooled Analysis of Safety Data From Phases 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections , 2018, Open Forum Infectious Diseases.
[4] Jian Zhou,et al. Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline , 2018, Antimicrobial Agents and Chemotherapy.
[5] D. Nicolau,et al. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. , 2018, International journal of antimicrobial agents.
[6] D. Snydman,et al. Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates , 2018, Antimicrobial Agents and Chemotherapy.
[7] J. Karlowsky,et al. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. , 2017, Diagnostic microbiology and infectious disease.
[8] P. Higgins,et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. , 2018, International journal of antimicrobial agents.
[9] S. Redican,et al. Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects , 2017, Open Forum Infectious Diseases.
[10] R. Bonomo,et al. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[11] Ionut Negoi,et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections , 2017, World Journal of Emergency Surgery.
[12] D. Andes,et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model , 2017, Antimicrobial Agents and Chemotherapy.
[13] J. Solomkin,et al. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial , 2016, JAMA surgery.
[14] M. Rosengart,et al. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. , 2017, Surgical infections.
[15] I. Morrissey,et al. In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013–2015) , 2016 .
[16] I. Morrissey,et al. In Vitro Global Surveillance of Eravacycline and Comparators against Staphylococcus spp. and Enterococcus spp. Over a Three-year Period (2013-15) , 2016 .
[17] P. Nordmann,et al. Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Gene mcr-1 , 2016, Antimicrobial Agents and Chemotherapy.
[18] M. Boermeester,et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) , 2016, World Journal of Emergency Surgery.
[19] Y. Hamada,et al. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms , 2016, Antimicrobial Agents and Chemotherapy.
[20] N. Woodford,et al. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.
[21] J. Karlowsky,et al. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent , 2016, Drugs.
[22] A. Pantosti,et al. Antimicrobial resistance: a global multifaceted phenomenon , 2015, Pathogens and global health.
[23] Ventola Cl,et al. The antibiotic resistance crisis: part 2: management strategies and new agents. , 2015, P & T : a peer-reviewed journal for formulary management.
[24] T. Grossman,et al. Eravacycline (TP-434) Is Efficacious in Animal Models of Infection , 2015, Antimicrobial Agents and Chemotherapy.
[25] D. Landman,et al. Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City , 2014, Antimicrobial Agents and Chemotherapy.
[26] Daniel N. Wilson,et al. Tetracycline antibiotics and resistance mechanisms , 2014, Biological chemistry.
[27] H. Giamarellou,et al. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches , 2014, Expert opinion on pharmacotherapy.
[28] J. Solomkin,et al. Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections , 2013, Antimicrobial Agents and Chemotherapy.
[29] T. Grossman,et al. Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens , 2013, Antimicrobial Agents and Chemotherapy.
[30] Daniel N. Wilson,et al. Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic , 2012, Antimicrobial Agents and Chemotherapy.
[31] M. Rönn,et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. , 2012, Journal of medicinal chemistry.
[32] M. Rönn,et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. , 2012, Journal of medicinal chemistry.